Additionally, the prevalence of oncogenic drivers in NSCLC, including mutations in EGFR, KRAS (e.g. G12C), and B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E, as well as gene rearrangements involving anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), neurotrophic tyrosine receptor kinase (NTRK), rearranged during transfection (RET), and MET, varies significantly across populations. This evidence concerns the gene MARK2 and non-small cell lung carcinoma.